Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Employees

423

Sector

Biotechnology & Medical Research

Calendar

Aug. 20 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-11	24.09 $	-1.55%	1,140,941
25-07-10	24.47 $	-3.62%	1,234,472
25-07-09	25.39 $	+5.62%	1,888,127
25-07-08	24.04 $	-0.04%	770,153
25-07-07	24.05 $	-0.58%	441,596

Delayed Quote Australian S.E., July 11, 2025 at 02:10 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.47AUD

Average target price

32.05AUD

Spread / Average Target

+30.97%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Australian S.E. Other stock markets 02:10:26 2025-07-11 am EDT			5-day change	1st Jan Change
24.09 ^AUD	-1.55%		+0.58%	-2.11%

Jul. 10	Telix Pharmaceuticals Limited Receives Permanent HCPCS Code for Gozellix from U.S. Centers for Medicare & Medicaid Services	CI
Jul. 08	Telix's Prostate Cancer Imaging Agent Gozellix Secures US Reimbursement Code, Shares Up 6%	MT

Capitalization	8.28B 5.43B 4.65B 4.33B 4.01B 7.44B 466B 51.81B 19.79B 218B 20.38B 19.96B 796B	P/E ratio 2025 *	44.8x	P/E ratio 2026 *	29.2x
Enterprise value	8.42B 5.53B 4.73B 4.41B 4.08B 7.57B 474B 52.71B 20.13B 222B 20.74B 20.31B 810B	EV / Sales 2025 *	6.61x	EV / Sales 2026 *	5.11x
Free-Float	58.65%	Yield 2025 *	-	Yield 2026 *	-

Telix Pharmaceuticals Limited Receives Permanent HCPCS Code for Gozellix from U.S. Centers for Medicare & Medicaid Services	Jul. 10	CI
Telix's Prostate Cancer Imaging Agent Gozellix Secures US Reimbursement Code, Shares Up 6%	Jul. 08	MT
HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	Jul. 03	MT
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses	Jun. 25	CI
Telix Says Illuccix Wins FDA Approval for Patient Selection for Pre-Taxane Radioligand Therapy	Jun. 23	MT
Telix Pharmaceuticals Limited Approves in U.S. for Patient Selection for Pre-Taxane RLT	Jun. 23	CI
Telix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement	Jun. 22	MT
Telix Precision Medicine Announces AlFluor Radiochemistry Platform	Jun. 20	CI
Telix Pharmaceuticals Limited Announces Prostate Cancer PSMA-PET Imaging Agent Approved in Greece	Jun. 13	CI
Telix Pharmaceuticals Limited - Analyst/Investor Day	Jun. 11
Telix Pharmaceuticals Announces Gozellix Now Available Nationally In U.S.	Jun. 11	RE
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S	Jun. 11	CI
Telix Opens Manufacturing Facility in Japan	Jun. 05	MT

HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	Jul. 03	MT
Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	Jun. 05	MT
UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	Jan. 27	MT
Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target is AU$21.30	24-08-23	MT
Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$22.55 From AU$22.49, Keeps at Buy	24-07-30	MT

Telix Pharmaceuticals Limited Stock

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Valuation: Telix Pharmaceuticals Limited

Chart: Telix Pharmaceuticals Limited

Latest news: Telix Pharmaceuticals Limited

Last Transcript: Telix Pharmaceuticals Limited

Analysts' recommendations: Telix Pharmaceuticals Limited

Press Releases: Telix Pharmaceuticals Limited

News in other languages: Telix Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Telix Pharmaceuticals Limited

ETFs: Telix Pharmaceuticals Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Gozellix Receives Permanent HCPCS Code	Jul. 09	AQ
Telix Pharmaceuticals : Application for quotation of securities - TLX	Jul. 08	PU
Telix Pharmaceuticals : Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses	Jun. 25	PU
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT	Jun. 23	AQ
Telix Precision Medicine Announces AlFluor Radiochemistry Platform	Jun. 20	AQ

Telix Pharmaceuticals Limited schließt die Übernahme von ARTMS, Inc. ab.	24-04-11
Telix Pharmaceuticals Limited completa la adquisición de ARTMS Inc.	24-04-11
Mauna Kea: la biotech Telix acquiert 19% du capital pour 6 millions d'euros	23-11-13
En Direct des Marchés : Airbus, TotalEnergies, Eramet, Valneva, BAE Systems, Novo Nordisk, Solvay...	23-11-13
Mauna Kea Technologies et Telix Pharmaceuticals entendent renforcer leur partenariat dans le domaine de la chirurgie uro-oncologique	23-11-13

1 day	-1.55%
1 week	+0.58%
Current month	-1.35%
1 month	-7.27%
3 months	-9.37%
6 months	+0.42%
Current year	-2.11%

1 week	23.57	25.87
1 month	22.76	26.25
Current year	21.4	31.97
1 year	17.03	31.97
3 years	4.37	31.97
5 years	1.24	31.97
10 years	0.46	31.97

Manager	Title	Age	Since
Christian Behrenbruch CEO	Chief Executive Officer	50	2017-01-02
Darren Smith DFI	Director of Finance/CFO	59	2022-07-30
Michael Wheatcroft CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Christian Behrenbruch BRD	Director/Board Member	50	2017-01-02
Mark Nelson BRD	Director/Board Member	65	2017-09-16
Jann Skinner BRD	Director/Board Member	67	2018-06-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TELIX PHARMACEUTICALS LIMITED	-1.55%	+0.58%	+37.26%	+342.02%	5.43B
LONZA GROUP AG	-0.95%	+1.11%	+10.39%	-1.05%	50.45B
BEONE MEDICINES LTD.	-0.90%	+3.22%	+73.51%	+34.25%	30.01B
CELLTRION, INC.	+1.42%	+5.74%	+4.18%	+11.14%	28.73B
IQVIA HOLDINGS INC.	+2.17%	+0.53%	-22.30%	-24.53%	28.64B
EUROFINS SCIENTIFIC SE	-0.20%	-0.85%	+26.70%	-22.30%	12.7B
ICON PUBLIC LIMITED COMPANY	+1.02%	+1.31%	-53.73%	-30.23%	12.08B
ASCENDIS PHARMA A/S	+0.44%	+1.33%	+28.51%	+88.54%	10.69B
QIAGEN N.V.	+1.23%	-0.19%	+17.83%	-5.21%	10.51B
TEMPUS AI, INC.	+2.04%	-2.25%	+70.29%	-	10.32B
Average	+0.35%	-0.65%	+19.26%	+43.63%	19.96B
Weighted average by Cap.	+0.27%	-0.57%	+16.64%	+14.24%

	2025 *	2026 *
Net sales	1.27B 836M 715M 667M 616M 1.14B 71.7B 7.97B 3.04B 33.5B 3.14B 3.07B 122B	1.62B 1.06B 908M 846M 782M 1.45B 90.99B 10.12B 3.86B 42.51B 3.98B 3.9B 155B
Net income	215M 141M 121M 112M 104M 193M 12.08B 1.34B 513M 5.64B 528M 517M 20.63B	333M 219M 187M 174M 161M 299M 18.75B 2.08B 796M 8.76B 820M 803M 32.01B
Net Debt	144M 94.62M 80.96M 75.44M 69.76M 129M 8.11B 902M 344M 3.79B 355M 348M 13.86B	-24.92M -16.35M -13.99M -13.04M -12.06M -22.38M -1.4B -156M -59.53M -655M -61.32M -60.07M -2.39B